Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- Govt Panel Members Call for Medication Control to Eliminate Unused Drugs
April 17, 2015
- Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
- Who Will Foot the Bill for Cost-Effective Assessments?: Chuikyo Chair
April 16, 2015
- Japan Faces Imperative to Increase Biostatisticians to Boost Clinical Research Quality
April 16, 2015
- PAFSC 1st Committee to Discuss Add’l Indication for Cymbalta on April 28
April 15, 2015
- “Proper Management” Essential in Company Funding of Academic Research: MHLW Official
April 15, 2015
- PMDA Invites People with Broad Perspective from the Medical Community to Join PMDA: Chief Executive
April 15, 2015
- MHLW Official Introduces Patient ADR Reporting System
April 15, 2015
- Cost-Effectiveness Case Study to Be Reported to Chuikyo in May: Official
April 14, 2015
- If Cost-Effective Assessment Is Used to Set Drug Prices, Focus Will Be on Impact on Pricing Rules: Ex-Chuikyo Member
April 14, 2015
- Industry Won’t Grow If Pricing Premium Ended, Pharma Leaders Tell Govt
April 14, 2015
- JPA’s Abe Says Link between Pricing Premium and New Drug Development Blurry
April 13, 2015
- PAFSC’s Second Committee to Review PegIntron, Talion on April 24
April 13, 2015
- Consumer Affairs Agency Warns Public of Adverse Reaction Risks of OTC Drugs
April 10, 2015
- Set Ceiling for Health Coverage of OTC-Like Drugs: Govt Panel
April 9, 2015
- Chuikyo to Focus Sights on Unused Medication, Long-Term Prescriptions in Discussions
April 9, 2015
- Orphan Designation System Should Be Adjusted for Factors Including Company Scale: Report
April 8, 2015
- Most Cancer Drugs Would Cost Over 1 Million Yen a Month under Patient-Initiated Mixed Care: NCC
April 7, 2015
- MEXT Secures FY2015 Budgets for Generic Promotion Subsidy Project
April 7, 2015
- Overlapping of All-Case Surveys and EPPV Inefficient: Mr Uda of FPMAJ
April 7, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…